Barclays PLC Acquires 100,678 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Barclays PLC raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 352.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 129,210 shares of the company’s stock after acquiring an additional 100,678 shares during the period. Barclays PLC’s holdings in Neumora Therapeutics were worth $1,708,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NMRA. Charles Schwab Investment Management Inc. grew its holdings in shares of Neumora Therapeutics by 139.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after buying an additional 406,891 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Neumora Therapeutics in the third quarter valued at $1,097,000. Callan Capital LLC increased its stake in Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after buying an additional 456,207 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Neumora Therapeutics by 79.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company’s stock worth $1,099,000 after buying an additional 49,527 shares in the last quarter. Finally, Wexford Capital LP boosted its position in Neumora Therapeutics by 90.1% during the third quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock valued at $2,878,000 after purchasing an additional 103,285 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

Insider Activity

In related news, insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now directly owns 322,966 shares of the company’s stock, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the sale, the director now directly owns 20,100 shares of the company’s stock, valued at $342,303. This represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Monday, December 16th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.40.

Neumora Therapeutics Price Performance

Shares of NMRA opened at $11.33 on Friday. The firm has a 50 day simple moving average of $11.07 and a two-hundred day simple moving average of $11.56. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00. The company has a market cap of $1.83 billion, a P/E ratio of -6.06 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter in the previous year, the company posted ($1.14) earnings per share. On average, analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.